BioPorto为肾损伤测试筹集了510万美元,目的是获得美国林业发展局的批准。 BioPorto raises $5.1M for kidney injury test, aiming for U.S. FDA approval.

BioPorto A/S是一家为早期发现肾损伤进行测试的公司,它通过出售新股票筹集了约510万美元。 BioPorto A/S, a company that develops tests for early detection of kidney injuries, has raised about $5.1 million through selling new shares. 这些资金将用于临床试验,以便林业发展局核准美国成人的ProNephro AKITM NGAL测试,并促进他们的商业活动。 The funds will go towards clinical trials for FDA approval of their ProNephro AKI™ NGAL test for adults in the U.S. and to boost their commercial operations. 新股份将在2025年4月30日前在哥本哈根的Nasdaq市上市。 The new shares will be listed on Nasdaq Copenhagen by April 30, 2025.